HUT74180A - Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation pharmaceutical compositions containing them and process for producing them - Google Patents
Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation pharmaceutical compositions containing them and process for producing themInfo
- Publication number
- HUT74180A HUT74180A HU9601455A HU9601455A HUT74180A HU T74180 A HUT74180 A HU T74180A HU 9601455 A HU9601455 A HU 9601455A HU 9601455 A HU9601455 A HU 9601455A HU T74180 A HUT74180 A HU T74180A
- Authority
- HU
- Hungary
- Prior art keywords
- producing
- treatment
- pharmaceutical compositions
- compositions containing
- substituted pyrazolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/160,594 US5466823A (en) | 1993-11-30 | 1993-11-30 | Substituted pyrazolyl benzenesulfonamides |
US08/223,629 US5521207A (en) | 1993-11-30 | 1994-04-06 | Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation |
PCT/US1994/012720 WO1995015316A1 (en) | 1993-11-30 | 1994-11-14 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Publications (3)
Publication Number | Publication Date |
---|---|
HU9601455D0 HU9601455D0 (en) | 1996-07-29 |
HUT74180A true HUT74180A (en) | 1996-11-28 |
HU223824B1 HU223824B1 (hu) | 2005-02-28 |
Family
ID=26857022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9601455A HU223824B1 (hu) | 1993-11-30 | 1994-11-14 | Gyulladáscsökkentő hatású szubsztituált pirazolil-benzol-szulfonamid-származékok, ilyen vegyületeket tartalmazó gyógyszerkészítmények és eljárás azok előállítására |
Country Status (26)
Country | Link |
---|---|
US (2) | US5760068A (hu) |
EP (1) | EP0731795B1 (hu) |
JP (3) | JP3025017B2 (hu) |
KR (3) | KR100229343B1 (hu) |
CN (4) | CN1268614C (hu) |
AT (4) | ATE219937T1 (hu) |
CA (4) | CA2177576C (hu) |
CY (2) | CY2237B1 (hu) |
CZ (1) | CZ294630B6 (hu) |
DE (6) | DE69432193T2 (hu) |
DK (3) | DK0924201T3 (hu) |
ES (4) | ES2172959T3 (hu) |
FI (1) | FI115053B (hu) |
FR (1) | FR09C0007I2 (hu) |
GR (1) | GR3032696T3 (hu) |
HK (2) | HK1013649A1 (hu) |
HU (1) | HU223824B1 (hu) |
LU (2) | LU90698I2 (hu) |
NL (1) | NL300024I2 (hu) |
NO (1) | NO306460B1 (hu) |
NZ (3) | NZ336428A (hu) |
PL (1) | PL180717B1 (hu) |
PT (3) | PT731795E (hu) |
RO (1) | RO118291B1 (hu) |
RU (1) | RU2139281C1 (hu) |
WO (1) | WO1995015316A1 (hu) |
Families Citing this family (250)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492411B1 (en) | 1993-11-30 | 2002-12-10 | G. D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
US6716991B1 (en) | 1993-11-30 | 2004-04-06 | G. D. Searle & Co. | Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
AU3815495A (en) * | 1994-11-08 | 1996-05-31 | Eisai Co. Ltd. | Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
AU708964B2 (en) * | 1995-05-25 | 1999-08-19 | G.D. Searle & Co. | Method of preparing 3-haloalkyl-1h-pyrazoles |
CA2223154A1 (en) | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
EP0833622B8 (en) * | 1995-06-12 | 2005-10-12 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
US6342510B1 (en) * | 1995-06-12 | 2002-01-29 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist |
US5968974A (en) | 1995-07-19 | 1999-10-19 | Merck & Co., Inc. | Method of treating colonic adenomas |
US6593361B2 (en) | 1995-07-19 | 2003-07-15 | Merck & Co Inc | Method of treating colonic adenomas |
US5756529A (en) * | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
GB9520584D0 (en) * | 1995-10-09 | 1995-12-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
KR19990064310A (ko) * | 1995-10-17 | 1999-07-26 | 윌리암스 로저 에이 | 시클로옥시게나제-2의 검출방법 |
CA2246265A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors |
EP0880363B1 (en) | 1996-02-13 | 2002-09-11 | G.D. SEARLE & CO. | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor |
CA2246356A1 (en) * | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist |
US5908858A (en) * | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
PL195955B1 (pl) * | 1996-04-12 | 2007-11-30 | Searle & Co | Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie |
US5677318A (en) * | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
ES2224222T3 (es) * | 1996-10-15 | 2005-03-01 | G.D. Searle Llc | Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de neoplasias. |
IT1287174B1 (it) * | 1996-11-15 | 1998-08-04 | Angelini Ricerche Spa | Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono |
RO118566B1 (ro) * | 1996-11-19 | 2003-07-30 | Searle & Co | Metoda pentru prevenirea si tratamentul unei boli asociata cu angiogeneza |
WO1998043648A1 (en) * | 1997-04-03 | 1998-10-08 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia |
NZ500141A (en) * | 1997-04-18 | 2002-05-31 | G | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
AUPO941497A0 (en) * | 1997-09-24 | 1997-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Novel compounds |
AU750356B2 (en) * | 1997-09-24 | 2002-07-18 | Fujisawa Pharmaceutical Co., Ltd. | 1,5-diphenylpyrazole derivatives |
FR2769311B1 (fr) * | 1997-10-07 | 1999-12-24 | Union Pharma Scient Appl | Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique |
US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
AUPP042397A0 (en) * | 1997-11-18 | 1997-12-11 | Fujisawa Pharmaceutical Co., Ltd. | 5-arylpyrazole compounds |
US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
US6887893B1 (en) | 1997-12-24 | 2005-05-03 | Sankyo Company, Limited | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia |
WO1999051580A1 (en) * | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
US6294558B1 (en) | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
US6727238B2 (en) | 1998-06-11 | 2004-04-27 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
USRE39708E1 (en) | 1998-08-07 | 2007-06-26 | Chiron Corporation | Estrogen receptor modulators |
CA2348979A1 (en) * | 1998-11-02 | 2000-05-11 | Merck & Co., Inc. | Method of treating migraines and pharmaceutical compositions |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
US20010024664A1 (en) * | 1999-03-19 | 2001-09-27 | Obukowicz Mark G. | Selective COX-2 inhibition from edible plant extracts |
WO2000066562A1 (en) * | 1999-05-03 | 2000-11-09 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
CO5261541A1 (es) * | 1999-05-14 | 2003-03-31 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de la migrana |
WO2000069434A1 (en) * | 1999-05-17 | 2000-11-23 | Ilex Oncology, Inc. | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
CO5190664A1 (es) | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
DE60004001T2 (de) | 1999-12-03 | 2004-04-15 | Pfizer Products Inc., Groton | Acetylenderivate zur Verwendung als schmerzstillendes oder entzündungshemmendes Mittel |
ES2193921T3 (es) | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
TR200302047T4 (tr) | 1999-12-03 | 2004-01-21 | Pfizer Products Inc. | Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri. |
ATE291019T1 (de) | 1999-12-03 | 2005-04-15 | Pfizer Prod Inc | Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen |
JP2004500358A (ja) * | 1999-12-08 | 2004-01-08 | ファルマシア コーポレイション | バイオアベイラビリティーが増加した固体状態のセレコキシブ |
UA74539C2 (en) * | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
PL351944A1 (en) * | 1999-12-08 | 2003-07-14 | Pharmacia Corp | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
OA11831A (en) * | 1999-12-08 | 2005-08-23 | Pharmacia Corp | Polymorphic crystalline forms of celecoxib. |
US6649629B2 (en) | 1999-12-23 | 2003-11-18 | Nitromed, Inc. | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
US20030158245A1 (en) * | 2000-03-31 | 2003-08-21 | Tsuneo Yasuma | Fused heterocyclic derivatives, their production and use |
JP2003531202A (ja) * | 2000-04-25 | 2003-10-21 | ファルマシア・コーポレーション | 3,4−ジ(カルボシクリルまたはヘテロシクリル)チオフェンの位置選択的合成 |
US6403629B2 (en) * | 2000-05-02 | 2002-06-11 | J.B. Chemical And Pharmaceuticals Limited | Heterocyclic compounds for therapeutic use |
MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
EA200802070A1 (ru) * | 2000-06-13 | 2009-06-30 | Вайет | Болеутоляющее и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2 |
TR200001872A3 (tr) * | 2000-06-26 | 2002-01-21 | Fako Ilaclari A.S | 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem. |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
WO2002005848A2 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
NZ524252A (en) | 2000-07-20 | 2004-03-26 | Lauras As | Cox-2 inhibitors for treating HIV and AIDS |
US6716829B2 (en) | 2000-07-27 | 2004-04-06 | Pharmacia Corporation | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
GB0021494D0 (en) * | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
US20030219461A1 (en) * | 2000-09-12 | 2003-11-27 | Britten Nancy J. | Parenteral combination therapy for infective conditions |
US20020122836A1 (en) * | 2000-12-15 | 2002-09-05 | Pharmacia Corporation | Selective COX-2 inhibition from non-edible plant extracts |
AU2002229074A1 (en) * | 2000-12-15 | 2002-06-24 | Pharmacia Corporation | Selective cox-2 inhibition from plant extracts |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US20030008870A1 (en) * | 2001-02-02 | 2003-01-09 | Joel Krasnow | Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dysmenorrhea |
ITMI20010733A1 (it) | 2001-04-05 | 2002-10-05 | Recordati Chem Pharm | Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria |
US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
US6673818B2 (en) | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
GB0112802D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0112810D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
US20060167074A1 (en) * | 2001-06-19 | 2006-07-27 | Norbert Muller | Methods and compositions for the treatment of psychiatric disorders |
DE10129320A1 (de) * | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
EP1273582B1 (en) | 2001-07-05 | 2005-06-29 | Pfizer Products Inc. | Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
DE10135027A1 (de) * | 2001-07-18 | 2003-02-06 | Solvay Pharm Gmbh | Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
GB0119477D0 (en) * | 2001-08-09 | 2001-10-03 | Glaxo Group Ltd | Pyrimidine derivatives |
US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
BR0211836A (pt) * | 2001-08-10 | 2004-12-14 | Pharmacia Corp | Inibidor de anidrase carbÈnica |
US20040067992A1 (en) * | 2001-08-10 | 2004-04-08 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
US20030220376A1 (en) * | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
US20030114418A1 (en) * | 2001-08-14 | 2003-06-19 | Pharmacia Corporation | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor |
US20030114416A1 (en) * | 2001-08-14 | 2003-06-19 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
US20050101563A1 (en) * | 2001-08-14 | 2005-05-12 | Pharmacia Corporation | Method and compositions for the treatment and prevention of pain and inflammation |
AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
EP1444207A2 (en) * | 2001-09-19 | 2004-08-11 | Pharmacia Corporation | Substituted pyrazolyl-compounds for the treatment of inflammation |
PE20030547A1 (es) * | 2001-09-24 | 2003-08-18 | Bayer Corp | Derivados de imidazol para el tratamiento de la obesidad |
GT200200183A (es) | 2001-09-28 | 2003-05-23 | Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol | |
WO2003037336A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer |
DE10162121A1 (de) * | 2001-12-12 | 2003-06-18 | Berolina Drug Dev Ab Svedala | Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel |
US20040062823A1 (en) * | 2001-12-13 | 2004-04-01 | Obukowicz Mark G. | Selective cox-2 inhibition from non-edible plant extracts |
US20040126438A1 (en) * | 2001-12-13 | 2004-07-01 | Obukowicz Mark G. | Selective cox-2 inhibition from plant extracts |
US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
WO2004026235A2 (en) * | 2002-09-20 | 2004-04-01 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
CA2477923C (en) * | 2002-03-01 | 2021-02-23 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
TW562937B (en) * | 2002-03-26 | 2003-11-21 | Nanya Technology Corp | Method for fast determining defect type of word line |
WO2003086287A2 (en) * | 2002-04-08 | 2003-10-23 | The Ohio State University Research Foundation | Compounds and methods for inducing apoptosis in proliferating cells |
MXPA04010186A (es) * | 2002-04-18 | 2005-02-03 | Pharmacia Corp | Monoterapia para el tratamiento de la enfermedad de parkinson con inhibidor (es) de la ciclooxigenasa-2 (cox 2). |
EP1494664A2 (en) * | 2002-04-18 | 2005-01-12 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
AU2003220483A1 (en) * | 2002-05-09 | 2003-11-11 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
AU2003241603B2 (en) * | 2002-05-24 | 2008-05-15 | Pharmacia Corporation | Synthesis of diaryl pyrazoles |
MXPA05000232A (es) | 2002-06-21 | 2005-06-17 | Transform Pharmaceuticals Inc | Composiciones farmaceuticas con disolucion mejorada. |
EP1534683A4 (en) * | 2002-06-27 | 2005-08-24 | Nitromed Inc | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHOD OF USE |
WO2004002420A2 (en) * | 2002-06-28 | 2004-01-08 | Nitromed, Inc. | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
KR100467668B1 (ko) * | 2002-08-07 | 2005-01-24 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
EP1546128B1 (en) * | 2002-08-19 | 2006-05-03 | Glaxo Group Limited | Pyrimidine derivatives as selective cox-2 inhibitors |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
GB0227443D0 (en) * | 2002-11-25 | 2002-12-31 | Glaxo Group Ltd | Pyrimidine derivatives |
AU2003295846A1 (en) * | 2002-11-26 | 2004-06-18 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
DE60332387D1 (de) | 2002-12-13 | 2010-06-10 | Warner Lambert Co | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege |
US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
US20040235925A1 (en) * | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
US20080153894A1 (en) * | 2002-12-19 | 2008-06-26 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
ES2215474B1 (es) | 2002-12-24 | 2005-12-16 | J. URIACH & CIA S.A. | Nuevos derivados de fosforamida. |
US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
EP2339328A3 (en) | 2002-12-30 | 2011-07-13 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of celecoxib |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1601353A4 (en) * | 2003-01-29 | 2008-08-13 | Childrens Medical Center | PREVENT OPERATIONAL ADVANCES WITH SELECTIVE COX-2 INHIBITORS |
US20040220155A1 (en) * | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
US20060142368A1 (en) * | 2003-04-08 | 2006-06-29 | Ching-Shih Chen | Compounds and methods for inducing apoptosis in proliferating cells |
PL1745791T3 (pl) | 2003-05-07 | 2013-11-29 | Osteologix As | Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu |
ES2394782T3 (es) * | 2003-05-07 | 2013-02-05 | Osteologix A/S | Composición con estroncio y vitamina D para la profilaxis y/o tratamiento de afecciones de cartílagos y/o huesos |
CN1309717C (zh) * | 2003-06-03 | 2007-04-11 | 李小虎 | 4-芳基-5h-噻吩-2-酮衍生物、其制法和用途 |
GB0319037D0 (en) * | 2003-08-13 | 2003-09-17 | Glaxo Group Ltd | 7-Azaindole Derivatives |
US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
US20060079566A1 (en) * | 2003-10-03 | 2006-04-13 | Ching-Shih Chen | PDK-1/Akt signaling inhibitors |
CN1889949B (zh) * | 2003-10-03 | 2010-06-16 | 俄亥俄州州立大学研究基金会 | PDK-1/Akt信号传导抑制剂 |
WO2005054204A2 (en) * | 2003-11-26 | 2005-06-16 | Synchrony Biosciences, Inc. | Pharmaceutical compounds that regenerate in vivo |
JPWO2005054181A1 (ja) | 2003-12-01 | 2007-12-06 | 株式会社リバース・プロテオミクス研究所 | 抗癌剤の新規標的タンパク質および対応する新規抗癌剤(スプナール) |
US7070816B2 (en) | 2003-12-05 | 2006-07-04 | New Chapter, Inc. | Methods for treating prostatic intraepithelial neoplasia with herbal compositions |
US7067159B2 (en) | 2003-12-05 | 2006-06-27 | New Chapter, Inc. | Methods for treating prostate cancer with herbal compositions |
TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
JP4718453B2 (ja) * | 2004-04-12 | 2011-07-06 | 武田薬品工業株式会社 | Gタンパク質共役型レセプタータンパク質の新規リガンドとその用途 |
ITMI20041032A1 (it) | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
JP2008518924A (ja) * | 2004-10-28 | 2008-06-05 | セルジーン・コーポレーション | 中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物 |
CA2589167A1 (en) | 2004-11-23 | 2006-06-01 | Pliva Hrvatska D.O.O. | Extended release pharmaceutical composition of celecoxib |
US20090036435A1 (en) | 2005-01-21 | 2009-02-05 | Astex Therapeutics Limited | Pharmaceutical Compounds |
US7521435B2 (en) | 2005-02-18 | 2009-04-21 | Pharma Diagnostics, N.V. | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
WO2006133926A1 (en) * | 2005-06-17 | 2006-12-21 | Carex Sa | Pyrazole derivates as cannabinoid receptor modulators |
KR101363278B1 (ko) | 2005-06-27 | 2014-02-21 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | 이미다졸계 lxr 변조제 |
HUP0500730A2 (en) * | 2005-07-29 | 2007-02-28 | Richter Gedeon Vegyuszeti Gyar | 1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use |
WO2007016677A2 (en) | 2005-08-02 | 2007-02-08 | Nitromed, Inc. | Nitric oxide enhancing antimicrobial compounds, compositions and methods of use |
US7838023B2 (en) | 2005-11-16 | 2010-11-23 | Nitromed, Inc. | Furoxan compounds, compositions and methods of use |
EP1965774A2 (en) * | 2005-12-30 | 2008-09-10 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
CA2647859C (en) | 2006-03-29 | 2016-01-05 | Nitromed, Inc. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
US8128460B2 (en) * | 2006-09-14 | 2012-03-06 | The Material Works, Ltd. | Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
RS51940B (en) | 2006-12-22 | 2012-02-29 | Recordati Ireland Limited | Combined TH2δ LIGANAD THERAPY AND NSAID FOR LOWER URINARY TRACT DISORDERS |
FR2911136B1 (fr) * | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique. |
JP2010516679A (ja) * | 2007-01-19 | 2010-05-20 | マリンクロット インコーポレイテッド | 診断用および治療用シクロオキシゲナーゼ−2結合リガンド |
WO2008126899A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | 5員環へテロ環誘導体及びその医薬用途 |
US8039502B2 (en) | 2007-07-24 | 2011-10-18 | The Ohio State University Research Foundation | Anti-infective agents against intracellular pathogens |
US20090062364A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched celecoxib |
WO2009152647A1 (zh) | 2008-06-20 | 2009-12-23 | 江苏恩华药业股份有限公司 | 芳烷基哌啶衍生物及其在制备镇痛、镇静药物中的应用 |
JP5503655B2 (ja) | 2008-09-22 | 2014-05-28 | アレイ バイオファーマ、インコーポレイテッド | Trkキナーゼ阻害剤としての置換イミダゾ[1,2b]ピリダジン化合物 |
EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
JP5600111B2 (ja) | 2008-10-22 | 2014-10-01 | アレイ バイオファーマ、インコーポレイテッド | TRKキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピリミジン化合物 |
US8785466B2 (en) * | 2008-10-31 | 2014-07-22 | Loyola University Chicago | Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom |
US8686017B2 (en) * | 2008-10-31 | 2014-04-01 | Loyola University Chicago | Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom |
US20120108823A1 (en) | 2009-04-22 | 2012-05-03 | The Ohio State University Research Foundation | Anti-francisella agents |
WO2010150144A2 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Low dose pharmaceutical compositions of celecoxib |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
WO2011050944A1 (en) | 2009-10-28 | 2011-05-05 | Ratiopharm Gmbh | Formulations containing celecoxib |
WO2011055233A2 (en) | 2009-11-03 | 2011-05-12 | Actavis Group Ptc Ehf | Improved process for preparing celecoxib polymorph |
NZ700332A (en) | 2010-03-30 | 2017-06-30 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
KR101852169B1 (ko) | 2010-05-20 | 2018-04-26 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
WO2012061260A1 (en) * | 2010-11-01 | 2012-05-10 | The Ohio State University Research Foundation | Anti-staphylococcal celecoxib derivatives |
CN102746231A (zh) * | 2011-04-20 | 2012-10-24 | 天津药物研究院 | 塞来昔布制备工艺 |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
EP3406598B1 (en) | 2012-06-14 | 2020-01-29 | Mayo Foundation for Medical Education and Research | Pyrazole derivatives as inhibitors of stat3 |
CN102746232A (zh) * | 2012-07-03 | 2012-10-24 | 石药集团中诺药业(石家庄)有限公司 | 一种塞来昔布杂质的制备方法 |
US8859781B2 (en) | 2012-07-12 | 2014-10-14 | Euclises Pharmaceuticals, Inc. | No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents |
WO2014012000A2 (en) | 2012-07-12 | 2014-01-16 | Euclises Pharmaceuticals, Inc. | No-releasing guanidine-coxib anti-cancer agents |
WO2014018888A1 (en) | 2012-07-26 | 2014-01-30 | Confluence Life Sciences Inc. | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment |
PT2938191T (pt) | 2012-12-28 | 2018-05-09 | Dow Agrosciences Llc | Misturas fungicidas sinérgicas para controlo fúngico em cereais |
US9107947B2 (en) | 2013-01-31 | 2015-08-18 | The Penn State Research Foundation | Anti-cancer compositions and methods |
WO2014138616A2 (en) * | 2013-03-08 | 2014-09-12 | Translational Drug Development, Llc | Pyrazole compounds and methods of use thereof |
BR112015023214A8 (pt) | 2013-03-15 | 2019-12-24 | Verseon Corp | composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica |
PL2968297T3 (pl) | 2013-03-15 | 2019-04-30 | Verseon Corp | Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej |
SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
CN104974091B (zh) * | 2014-04-10 | 2018-01-02 | 沈阳药科大学 | 3‑甲基‑1,5‑二芳基吡唑类化合物及其制备方法和用途 |
RU2017112739A (ru) | 2014-09-17 | 2018-10-17 | Версеон Корпорейшн | Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз |
JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | (S)−N−(5−((R)−2−(2,5−ジフルオロフェニル)−ピロリジン−1−イル)−ピラゾロ[1,5−a]ピリミジン−3−イル)−3−ヒドロキシピロリジン−1−カルボキサミド硫酸水素塩の結晶形 |
BR112017013645A2 (pt) | 2014-12-30 | 2018-03-06 | Dow Agrosciences Llc | uso de compostos de picolinamida com atividade fungicida |
CA2972413A1 (en) | 2014-12-30 | 2016-07-07 | Dow Agrosciences Llc | Picolinamide compounds with fungicidal activity |
CR20170308A (es) | 2014-12-30 | 2017-08-10 | Dow Agrosciences Llc | Compuestos de picolinamida con actividad fungicida |
KR20170099928A (ko) | 2014-12-30 | 2017-09-01 | 다우 아그로사이언시즈 엘엘씨 | 살진균 활성을 갖는 피콜린아미드 |
JP2018500361A (ja) | 2014-12-30 | 2018-01-11 | ダウ アグロサイエンシィズ エルエルシー | 殺真菌剤としてのピコリンアミドの使用 |
KR20170103838A (ko) | 2015-01-23 | 2017-09-13 | 컨플루언스 라이프 사이언시스, 인코포레이티드 | 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CN107438607B (zh) | 2015-02-20 | 2021-02-05 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
SG10201907699YA (en) | 2015-02-27 | 2019-09-27 | Verseon Corp | Substituted pyrazole compounds as serine protease inhibitors |
EP3292213A1 (en) | 2015-05-04 | 2018-03-14 | Academisch Medisch Centrum | Biomarkers for the detection of aspirin insensitivity |
JP6605047B2 (ja) | 2015-05-28 | 2019-11-13 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 疼痛治療のためのセレコキシブの経口用組成物 |
CN104945388A (zh) * | 2015-07-09 | 2015-09-30 | 南京大学 | 4-(3-(3-(4-氯香豆素)-酰腙)-5-苯基-吡唑)苯磺酰胺类衍生物的制备方法及在抗癌药物中的应用 |
AU2016344058A1 (en) | 2015-10-26 | 2018-05-17 | Array Biopharma Inc. | Point mutations in Trk inhibitor-resistant cancer and methods relating to the same |
AU2017218437A1 (en) | 2016-02-10 | 2018-08-23 | Cocoon Biotech Inc. | Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs silk fibroin and a gelling agent and uses thereof |
TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
PL3800189T3 (pl) | 2016-05-18 | 2023-10-23 | Loxo Oncology, Inc. | Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo[1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu |
US10722456B2 (en) | 2016-05-27 | 2020-07-28 | Dr. Reddy's Laboratories Ltd | Oral composition of celecoxib for treatment of pain |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TW201842851A (zh) | 2017-05-02 | 2018-12-16 | 美商陶氏農業科學公司 | 用於穀類中的真菌防治之協同性混合物 |
TWI774761B (zh) | 2017-05-02 | 2022-08-21 | 美商科迪華農業科技有限責任公司 | 用於穀物中的真菌防治之協同性混合物 |
JP7112429B2 (ja) | 2017-05-02 | 2022-08-03 | コルテバ アグリサイエンス エルエルシー | 芝草上の真菌疾患に対する殺菌剤としての非環式ピコリンアミド化合物の使用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
SG11202002947TA (en) | 2017-11-03 | 2020-04-29 | Aclaris Therapeutics Inc | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
BR102019004480B1 (pt) | 2018-03-08 | 2023-03-28 | Dow Agrosciences Llc | Picolinamidas como fungicidas |
AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
KR20210044822A (ko) | 2018-08-10 | 2021-04-23 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 피롤로피리미딘 itk 억제제 |
CN111039982A (zh) * | 2018-10-12 | 2020-04-21 | 南京大学 | 一类含新型磷脂胺骨架的吡唑磺胺衍生物的设计、合成 |
EP3866597A4 (en) | 2018-10-15 | 2022-06-29 | Corteva Agriscience LLC | Methods for sythesis of oxypicolinamides |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
BR112021021477A2 (pt) | 2019-05-02 | 2021-12-21 | Aclaris Therapeutics Inc | Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP4275692A2 (en) | 2021-01-08 | 2023-11-15 | Seoul National University R & DB Foundation | Dried-cell-secretome-based therapeutic agent for treating osteoarthritis |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
CN114292235B (zh) * | 2021-12-29 | 2023-04-14 | 江苏天和制药有限公司 | 一种地拉考昔的制备和提纯方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146721A (en) * | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
US3940418A (en) * | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
GB8814587D0 (en) * | 1988-06-20 | 1988-07-27 | Erba Carlo Spa | Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5387693A (en) * | 1991-08-08 | 1995-02-07 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole intermediate compounds |
US5134155A (en) * | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
WO1994014777A1 (en) * | 1992-12-28 | 1994-07-07 | Eisai Co., Ltd. | Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar) |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
-
1994
- 1994-11-14 DK DK99101677T patent/DK0924201T3/da active
- 1994-11-14 CA CA002177576A patent/CA2177576C/en not_active Expired - Lifetime
- 1994-11-14 DK DK95902444T patent/DK0731795T3/da active
- 1994-11-14 PT PT95902444T patent/PT731795E/pt unknown
- 1994-11-14 DK DK99101697T patent/DK0923933T3/da active
- 1994-11-14 CN CNB2003101142478A patent/CN1268614C/zh not_active Expired - Lifetime
- 1994-11-14 RU RU96115039A patent/RU2139281C1/ru active
- 1994-11-14 ES ES99101677T patent/ES2172959T3/es not_active Expired - Lifetime
- 1994-11-14 ES ES99101697T patent/ES2180233T3/es not_active Expired - Lifetime
- 1994-11-14 KR KR1019960702677A patent/KR100229343B1/ko not_active IP Right Cessation
- 1994-11-14 AT AT99101697T patent/ATE219937T1/de active
- 1994-11-14 RO RO96-01100A patent/RO118291B1/ro unknown
- 1994-11-14 DE DE69432193T patent/DE69432193T2/de not_active Expired - Lifetime
- 1994-11-14 NZ NZ336428A patent/NZ336428A/en not_active IP Right Cessation
- 1994-11-14 CA CA002276946A patent/CA2276946A1/en not_active Abandoned
- 1994-11-14 CA CA002276945A patent/CA2276945C/en not_active Expired - Lifetime
- 1994-11-14 PL PL94314695A patent/PL180717B1/pl unknown
- 1994-11-14 ES ES99101687T patent/ES2193609T3/es not_active Expired - Lifetime
- 1994-11-14 JP JP7515611A patent/JP3025017B2/ja not_active Expired - Lifetime
- 1994-11-14 DE DE69422306A patent/DE69422306D1/de not_active Expired - Lifetime
- 1994-11-14 WO PCT/US1994/012720 patent/WO1995015316A1/en active Search and Examination
- 1994-11-14 CA CA002277954A patent/CA2277954A1/en not_active Abandoned
- 1994-11-14 EP EP95902444A patent/EP0731795B1/en not_active Expired - Lifetime
- 1994-11-14 KR KR1019997003745A patent/KR100263817B1/ko not_active IP Right Cessation
- 1994-11-14 HU HU9601455A patent/HU223824B1/hu active Protection Beyond IP Right Term
- 1994-11-14 DE DE69430930T patent/DE69430930T2/de not_active Expired - Lifetime
- 1994-11-14 DE DE69429836T patent/DE69429836T2/de not_active Expired - Lifetime
- 1994-11-14 AT AT99101677T patent/ATE212985T1/de active
- 1994-11-14 ES ES95902444T patent/ES2141916T3/es not_active Expired - Lifetime
- 1994-11-14 US US08/648,113 patent/US5760068A/en not_active Ceased
- 1994-11-14 PT PT99101677T patent/PT924201E/pt unknown
- 1994-11-14 NZ NZ536355A patent/NZ536355A/en not_active IP Right Cessation
- 1994-11-14 PT PT99101697T patent/PT923933E/pt unknown
- 1994-11-14 NZ NZ276885A patent/NZ276885A/xx not_active IP Right Cessation
- 1994-11-14 CN CN94194833A patent/CN1061036C/zh not_active Expired - Lifetime
- 1994-11-14 CZ CZ19961503A patent/CZ294630B6/cs not_active IP Right Cessation
- 1994-11-14 AT AT99101687T patent/ATE233245T1/de active
- 1994-11-14 DE DE2000175033 patent/DE10075033I2/de active Active
- 1994-11-14 AT AT95902444T patent/ATE187965T1/de active
- 1994-11-14 DE DE69422306T patent/DE69422306T4/de not_active Expired - Lifetime
-
1995
- 1995-09-27 US US08/534,757 patent/US5753688A/en not_active Expired - Lifetime
-
1996
- 1996-05-29 FI FI962249A patent/FI115053B/fi not_active IP Right Cessation
- 1996-05-29 NO NO962184A patent/NO306460B1/no not_active IP Right Cessation
-
1998
- 1998-12-23 HK HK98114923A patent/HK1013649A1/xx unknown
-
1999
- 1999-04-28 KR KR1019997003746A patent/KR100261669B1/ko not_active IP Right Cessation
- 1999-10-20 JP JP29887999A patent/JP3445762B2/ja not_active Expired - Lifetime
- 1999-12-15 CN CNB99126472XA patent/CN1134418C/zh not_active Expired - Lifetime
- 1999-12-15 CN CN99126471A patent/CN1127484C/zh not_active Expired - Lifetime
- 1999-12-23 HK HK99106091A patent/HK1021935A1/xx unknown
-
2000
- 2000-02-18 GR GR20000400394T patent/GR3032696T3/el unknown
- 2000-11-03 NL NL300024C patent/NL300024I2/nl unknown
- 2000-12-13 LU LU90698C patent/LU90698I2/fr unknown
-
2001
- 2001-06-21 CY CY0100013A patent/CY2237B1/xx unknown
-
2003
- 2003-01-06 JP JP2003032958A patent/JP3921451B2/ja not_active Expired - Lifetime
-
2009
- 2009-03-03 FR FR09C0007C patent/FR09C0007I2/fr active Active
- 2009-03-06 LU LU91538C patent/LU91538I2/fr unknown
- 2009-03-09 CY CY200900003C patent/CY2009003I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUT74180A (en) | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation pharmaceutical compositions containing them and process for producing them | |
AU2533392A (en) | New(benzocycloalkyl)alkylamines, a process for their preparation and pharmaceutical compositions containing them | |
PT772600E (pt) | Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao | |
HUT50842A (en) | Process for producing new diphosphonic acid derivatives and pharmaceutical compositions comprising same | |
IL66009A (en) | 2-aryl-3,4-diazabicyclo(4.n.o)alk-2-en-5-ones,their preparation and pharmaceutical compositions containing them | |
AU1306795A (en) | Anticonvulsant pseudofructopyranose sulfamates | |
IL124431A0 (en) | Sulfur containing dl-tert-butylphenol compounds useful as anti-inflammatory agents | |
CZ228195A3 (en) | Derivatives of hydroxymethylfurazancarboxylic acid, process of their preparation, their use for treating cardiovascular diseases and a pharmaceutical composition containing thereof | |
AU7000994A (en) | Phosphosuccinic acid derivatives and their use as medicaments | |
HUT49886A (en) | Process for producing new beta-lactam antibiotics and pharmaceutical compositions comprising same | |
GR3030731T3 (en) | Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them | |
CA2173158A1 (en) | Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HFG4 | Patent granted, date of granting |
Effective date: 20041222 |
|
AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: MAVACOXIB AND IT'S PHARMA-CEUTICALLY ACCEPTABLE SALTS; REG. NO/DATE: EU/2/08/084/001-005 20080909 Spc suppl protection certif: S0900004 Filing date: 20090306 Expiry date: 20141114 |
|
GB9A | Succession in title |
Owner name: G.D. SEARLE LLC, US Free format text: FORMER OWNER(S): G.D. SEARLE AND CO., US; G.D. SEARLE AND CO., US |
|
FG4S | Grant of supplementary protection certificate |
Free format text: PRODUCT NAME: MAVACOXIB AND IT'S PHARMA-CEUTICALLY ACCEPTABLE SALTS; REG. NO/DATE: EU/2/08/084/001-005 20080909 Spc suppl protection certif: S0900004 Filing date: 20090306 Expiry date: 20141114 Extension date: 20191114 |